GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Nouveau Life Pharmaceuticals NOUV · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2024

Net income

−$17,212

FY2024FY2024

Free cash flow

—

FY2024FY2024

Shareholders' equity

—

FY2024FY2024

Income statement

Fiscal years

FY2024
Operating income−$17,212
Net income−$17,212
Diluted earnings per share-0.00

Balance sheet

At each fiscal year end

FY2024
Shares outstanding6,661m

Cash flow

Fiscal years

Latest quarters

By quarter end

Mar 2025Dec 2024Mar 2024Mar 2023Dec 2022Mar 2012Sept 2011Jun 2011
Revenue——————$6,000$6,786
Gross profit—————−$20,000$550$6,786
Operating income−$5,616−$17,212−$6,407−$15,789−$15,789−$145,368$550$635
Net income−$5,616−$17,212−$6,407−$15,786−$15,786−$145,368$550$635
Diluted earnings per share-0.00-0.00-0.00-0.00-0.00-0.000.000.00
Total assets———$7,713$7,713$1,100$550$635
Cash and short-term investments———$7,713$7,713———
Shareholders' equity———−$95,550−$95,550−$146,268−$30,720−$30,635

Growth per year

Compound annual rate

3 years5 years10 years
Operating income—-42.3%—
Net income—-45.5%-23.6%

Valuation history

At each fiscal year end

FY2024
Price to earnings-1.2

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return700%655260%0%-79%700%31457180%-64%2700%3900%4509%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.